The global immunoassay market size was $24.30 billion in 2021 and is predicted to reach $45.82 billion by 2030 with a CAGR of 7.3% during the forecast period 2021-2030. North America is poised to lead the industry, followed by Europe.
Pathogens, such as bacteria, fungus, protozoa, worms, viruses, and prions, cause infectious diseases. The main function of the immunoassay is to defend the body from pathogens. Rapid pathogen identification from patient samples is critical for the proper diagnosis and treatment of infectious disorders.
The three categories of pathogen diagnostic instruments are:
Microbiology Testing studies the characteristics of pathogens, their modes of transmission, and mechanisms of infection and growth (Diagnosis takes up to 7 days).
Molecular Testing detects a molecule, often in low concentrations, as a marker of disease or risk in a sample taken from a patient. These tests are sensitive to viral nucleic acids. Hence the use of polymerase chain reaction (PCR) and other comparable nucleic acid amplification methods. (Diagnosed within a day)
Immunoassays- They are similar to Molecular Testing but detect proteins and antigens.
An assay is a process or a way of analyzing a substance to determine its quality or composition. Immunoassays are biochemical tests that use the binding ability of antibodies (immunoglobulin) and antigens (foreign substances) to detect and measure the concentration of target molecules. Traditional methods use cell culture to diagnose viruses, whereas most cultures take up to 7 days for accurate identification. Researchers and health care practitioners use immunoassay testing to detect various antibodies. Immunoassays are fast and accurate tests that can be performed on-site and in the lab to detect specific chemicals. When a patient is infected with a disease, the presence of antigens can be used to directly detect the infection. According to Global Burden of Disease (2017), Lower respiratory infections are the 3rd leading cause of early death and will remain the same till 2040.
Procedure- Immunoassay testing is performed by using antibodies to detect and identify small biological substances in the bloodstream and other bodily fluids. The procedure follows the concept that particular antigens bind to certain specific recently introduced antibodies, resulting in the stimulation of an immune response. Antibodies are highly specific to analytes (the substance in a test sample), such as nucleoproteins, hormones, and peptides. Detection of analytes becomes highly successful through the formation of antigen-antibody complexes. A colour change occurs, that indicates the presence of the analyte in question. The observed colour symbolizes the number of targeted molecules present in the test solution. In most cases, immunoassays provide results back in 24 hours. EIAs are less time-consuming than cytotoxicity tests, are less expensive, and provide results in 1 to 6 hours.
Cost- Test kits cost from $1.20 per test for ELISA to more than $30 for western blot.
According to HTStec Limited's publication Automated Immunoassays Trends, the median capital cost of immunoassay automation already implemented was in the range of $40-$60,000.
Benefits- Immunoassays can provide a fast, simple and more cost-effective detection than the conventional methods. It has high sensitivity and specificity, convenience, and the ability to achieve high throughput.
Applications- Immunoassays have a wide application that includes:
Diagnosis of diseases.
Therapeutic drug monitoring.
Clinical pharmacokinetics.
Bioequivalence studies in drug discovery.
Biopharmaceutical analysis.
Sports anti-doping analysis.
Pregnancy Test to detect the pregnancy marker.
Environmental monitoring.
Food testing.
Types of Immunoassay Platforms
Radioimmunoassay (RIA)- RIA is an immunoassay that uses radioactive isotopes (e.g. I-235) to label the antibody/antigen. It detects radioactivity to measure the antibody-antigen compound with very high sensitivity.
Enzyme Immunoassays (EIA)- EIA is possibly one of the most popular immunoassays. Instead of radioactive isotopes, Enzymes (such as HRP and AP) are used as probes in EIA. These enzymes are frequently detected because their enzymatic reactions result in a visible colour change.
Fluoroimmnoassay (FIA)- FIA is analogous to RIA except that the label which is a fluorophore (e.g. FITC, phycoerythrin) rather than radioisotope. A detecting device can directly measure the fluorescence signal.
Chemiluminescence immunoassay (CLIA)- CLIA is a method for determining sample concentrations based on the amount of luminescence produced by a chemical reaction.
Colloidal Gold Immunochromatographic Assay- ICA, also known as lateral flow immunoassay, is a rapid test immunoassay to detect a target analyte's presence (or absence) in a sample (matrix) without the need for specialized and costly equipment.
Electrochemiluminescence immunoassay (ECL)- When Electrochemiluminescent tags are triggered by electricity in the right chemical environment, they produce light.
Types of Immunoassay Techniques
Western Blotting-Western Blotting detects and identifies viral antigens (proteins usually on the surface of viruses) using antibodies against those particular proteins.
Enzyme-Linked Immunosorbent Assays-ELISA (Enzyme-Linked ImmunoSorbent Assay) uses virus antigen to detect antibodies.
Immuno-PCR -Compared to similar ELISA, I-PCR combines the simplicity and versatility of an enzyme-linked immunosorbent test (ELISA) with the exponential amplification capacity and sensitivity of PCR.
Rapid Tests-The rapid test involves the same technique as ELISA. However, it is low in sensitivity and specificity as compared to ELISA.
Enzyme-Linked Immunospot-It is a hybrid essay that combines the features of an MLR (Mixed leukocyte reaction), and ELISA used to determine HIV-1 specific CD8 T-cell responses.
CD/DVD-based immunoassay- It includes the disk (grey), gold nanoparticle (red), a probe (green), analyte (yellow), and silver particle (blue).
Market Dynamics
Key Industry Drivers (Rising Infections, Cancer Patients, old age population and Automation)
Key factors that promote the growth of the Immunoassay market
Rising Infections- Some of the conditions that may increase susceptibility to infectious diseases are cancers, particularly patients on chemo- or radiotherapy, leukaemia, lymphoma, Hodgkin's disease, immune suppression (HIV infection), long-term steroid use, liver disease, hemochromatosis, diabetes, alcoholism, chronic kidney disease, and dialysis patients who are diagnosed by immunoassays. According to the WHO, the last decade witnessed 20% of death worldwide due to infections. The most common causes of death related to infectious diseases were lower respiratory infections (6.1%), diarrheal diseases (4.3%), HIV/AIDS (3.1%), tuberculosis (2.4%), malaria (2%), and measles (1.6%).
Rising cases of Cancer Patients-The incidence of cancer is increasing steadily, which is expected to drive the demand for effective diagnostic methods such as immunoassay. This growth is due to chronic and infectious disorders, such as the COVID-19 outbreak. Infectious disorders including SARS-CoV2 (COVID-19), Hepatitis B, C, HIV, Dengue Malaria, Tuberculosis, and others are on the rise. According to the findings of the International Agency for Research on Cancer's GLOBOCAN 2020, there were 19.3 million new cancer cases and over 10.0 million cancer deaths in the year 2020.
Rise in the old age population- Old age people are more prone to chronic infectious and Immunodeficiency Diseases which is driving growth of the market. According to World Population Ageing 2019, the number of people aged 65 years or over will double in 30 years. Meanwhile, the number of people aged 80 years or over will rise threefold.
Automation-Fully automated immunoassays can provide high throughput, reproducibility, and ease of assay transfer. Process automation provides the dual benefits of time savings and reduction in operator-dependent variability.
Restraints (Wide Adoption of Molecular diagnostics and Operational Hurdles)
Wide Adoption of molecular diagnostic tests-Despite the fact that many laboratories now utilize molecular assays to detect viruses, immunoassays are still commonly used in the identification process because of their speed, sensitivity, accuracy, cost-effectiveness and convenience of use.
Operational hurdles- Immunoassay reagents and kits face operating issues like cross-reactivity of antibodies, low detection limits of the available antibody, and false negatives.
Various Opportunities Covered on the basis of Evolution of Companion diagnostics, High Success rate, Increase in Incidence of Sepsis, Emergence of Condition-specific biomarkers
Evolution of Companion diagnostics - The drug diagnostic co-development model is commonly used to create companion diagnostic assays parallel with a medication. There is an increase observed in the number of predictive biomarker assays being developed in recent years to guide the usage of targeted cancer therapies.
High Success rate - Immunoassays have grown in popularity to evaluate biological analytes due to their sensitivity, specificity, and ease of use. Furthermore, some immunoassay procedures are quick, precise, and simple to automate, needing minimal human intervention. The recent estimates published in The Lancet on the Performance characteristics of five immunoassays for SARS-CoV-2 accounted for sensitivity and specificity of more than 98%.
Increase in Incidence of Sepsis - Sepsis is a fatal disease when the body's response to an infection causes tissue damage. While bacterial infections are the most prevalent cause of sepsis, they can also be caused by viral infections. As Per the global Immunoassay market report on the Epidemiology and Burden of Sepsis 2017, sepsis led to 20% of annual global deaths (11 million deaths) and affected 49 million people.
The emergence of Condition-specific biomarkers - Many biomolecules are used as biomarkers, including antigens, DNA, mRNA, and enzymes. However, protein biomarkers are the most common biomarkers used in medical diagnostics. Tumour tissues, serum, and other bodily fluids all contain biomarkers. The field of biomarker detection technology has made tremendous progress. Various biomarker detection approaches have been developed based on extremely specific identification biomarkers. According to the article published in Infection & Chemotherapy Journal, biomarkers can be used for risk stratification, diagnosis, monitoring of treatment responses, and outcome prediction. C-reactive protein, procalcitonin, different cytokines, and cell surface markers are among the 170 biomarkers that have been useful for diagnosing infections.
The industry has been ramified based on Type/ Platform, Technique, Application End-user, Product, Specimen type and Region.
By Type/ Platform
Radioimmunoassay (RIA)
Enzyme Immunoassays (EIA)
Fluoroimmnoassay (FIA)
Chemiluminescenceimmunoassay (CLIA)
Electrochemiluminescence immunoassay (ECL)
Colloidal Gold Immunochromatographic Assay
By Technique
Western Blotting
Enzyme-Linked Immunosorbent Assays
Immuno-PCR (I-PCR)
Rapid Tests
Enzyme-Linked Immunospot
CD/DVD-based immunoassay
Other Techniques
By Application
Infectious Diseases
Respiratory Disease
Oncology or Cancer Diagnostics
Hematology
Cardiology
Endocrinology
Thyroid
Allergies
Others
By End-User
Hospitals
Pharma & Biotech Companies
Clinical Laboratories
By Product
Reagents and Kits
Analyzers
By Specimen Type
Blood
Saliva
Urine
By Region
North America
Europe
Asia-Pacific
Latin America
The Middle East and Africa
By Type/ Platform, Enzyme Immunoassays (EIA) are the most cost-effective since they are quick, easy to use, and do not require additional handling or disposal procedures. As a result, they control the majority of the market.
By Technique, Enzyme-linked immunosorbent assay (ELISA) leads the market segment of Immunoscreening. Certain diseases aren't easy to identify with other means like swab tests. An ELISA blood test can help spot signs of infection or disease in your system. The gold standard of immunoassays is the enzyme-linked immunosorbent assay (ELISA), a labelled immunoassay. This very sensitive immunological test detects and measures molecules such as antibodies, antigens, proteins, glycoproteins, and hormones. The significant industry share is due to the high use of immunoassay tests to detect and diagnose cancer, chronic complications and other infectious diseases.
Based on application, the Infectious diseases segment is leading the global Immunoassay market share due to the high incidence of infectious diseases, rising number of regulatory approvals & product launches, increased Adoption of kits, and increasing demand for COVID-19 test kits.
By End Users, the Hospital segment leads the market share as it facilitates in-house diagnostic laboratories. Rise in infectious diseases, which are mostly Hospital Acquired Infections are treatable in hospitals. The expanding number of tests performed in diagnostic labs, rising laboratory automation, availability of well-equipped immunoassay systems, rising prevalence of infectious disorders, and rising government initiatives drive this segment's expansion. The CDC estimates that Out of All 1.7 Million Hospital Acquired Infections (HAIs) in the US, 32% are urinary tract infections, 22% are surgical site infections, 15% are lung infections, and 14% are bloodstream infections.
By Product Type, the Reagents and kits segment is destined to dominate the immunoassay reagents and devices market because of its increased use in illness detection and drug development. The large industry share is attributed to their repetitive purchase and high consumption for diagnostic purposes.
By Specimen Type, the Blood segment is poised to lead the market share by revenue due to a large number of tests requiring high specificity performed using blood samples. Blood tests provide a crucial picture of overall health and well-being
By Region, North America is expected to dominate the market. The surge in the market share is due to the rise in the prevalence rates of chronic disorders and infectious diseases. Furthermore, the growing elderly population and well-established healthcare infrastructure will boost the growth of the region's immunoassay reagents and devices market. In nations like the United States with established market economies, infectious diseases account for 4.2% of all disability-adjusted life years lost (DALYs), whereas chronic and neoplastic diseases account for 81%, according to estimates from the Global Burden of Disease Study.
Asia-Pacific is projected to observe signs of growth during the forecast period due to the highest number of immunoassay reagents and device providers. According to the World Health Organization, ICU-acquired infections, such as UTIs and surgical-site wound infections, are two to three times greater in developing nations than in developed countries.
Report Attribute
Details
Forecast Period
2021 - 2030
The market size value in 2021
USD 24.30 Billion
The revenue forecast in 2030
USD 45.82 Billion
Growth rate
CAGR of 7.30%
The base year for estimation
2021
Historical data
2015 – 2021
Unit
USD Billion, CAGR (2021 - 2030)
Segmentation
By Type/ Platform, By Technique, By Application, By End-user, By Product, By Specimen Type and By Region.
Radioimmunoassay (RIA), Enzyme Immunoassays (EIA), Fluoroimmnoassay (FIA), Chemiluminescence immunoassay (CLIA), Electrochemiluminescence immunoassay (ECL), Colloidal Gold Immunochromatographic Assay
Western Blotting, Enzyme-Linked Immunosorbent Assays, Immuno-PCR (I-PCR), Rapid Tests, Enzyme-Linked Immunospot, CD/DVD-based immunoassay, Other Techniques
Infectious Diseases, Respiratory Disease, Oncology or Cancer Diagnostics, Hematology, Cardiology, Endocrinology, Thyroid, Allergies and Others
By End-user
Hospitals, Pharma & Biotech Companies, Clinical Laboratories and Others
Reagents and Kits and Analyzers
Blood, Saliva, Urine, Others
North America, Europe, Asia-Pacific, Middle-East and Africa, and South America.
Country Scope
Canada, Germany, UK, US, Mexico, France, India, Japan, China etc.
Company Profiles
BD, Bio-Techne, Abbott, Agilent Technologies, Beckman Coulter, BioCheck,bioMérieux SA, Merck KGaA, Ortho Clinical Diagnostics, Randox Laboratories Ltd, Siemens, Thermo Fisher Scientific, Shenzhen Mindray Bio-Medical Electronics Co, QIAGEN, PerkinElmer Inc, Meso Scale Diagnostics, F. Hoffmann-La Roche Ltd, DiaSorin S.p.A
Luminex Corporation, Bio-Rad Laboratories,
The report has the competitive landscape analysis, which details the most significant competitors operating in a global industry. The overall comparison is done on the basis of overall revenue generation, key investments by venture capitalists, market initiatives, company overview, production analysis, value chain optimization, R&D investment, share financials, global presence, production capacity, production sites and facilities, potential, and various other factors.
Key Players currently dominating the industry are:
Abbott
Agilent Technologies
BD
Beckman Coulter
BioCheck
bioMérieux SA
Bio-Rad Laboratories
Bio-Techne
DiaSorin S.p.A
F. Hoffmann-La Roche Ltd
Luminex Corporation
Merck KGaA
Meso Scale Diagnostics
Ortho Clinical Diagnostics
PerkinElmer Inc
QIAGEN
Quidel Corporation
Randox Laboratories Ltd
Shenzhen Mindray Bio-Medical Electronics Co
Siemens
Thermo Fisher Scientific
Recent Developments
In April 2022, GeneProof, a prominent molecular diagnostics firm based in Brno, Czech Republic, merged with American Laboratory Products Company, Ltd. (ALPCO), a speciality in vitro diagnostics company. The merger made them a global market leader in diagnostic products with extensive capabilities covering innovative immunoassay testing kits, real-time PCR testing products, and automated laboratory instrumentation systems.
In April 2022, The Simple Plex HEK 293 HCP 3G assay for automated process impurity detection on the Ella immunoassay platform was launched by Bio-Techne Corporation and Cygnus Technologies, a division of Maravai LifeSciences. In Gene and Cell Therapy applications, the purification of viral particles to reduce host cell protein (HCP) contamination is an important part of the viral production workflow. To guarantee HCP, impurity clearance is performed according to regulatory criteria, and accurate quantification throughout process phases is required.
In February 2022, NOVEOS Immunoassay Analyzer gained additional FDA 510(k) clearance from Hycor Biomedical Inc, a medical device firm that makes and supplies in-vitro diagnostic equipment. The NOVEOS Immunoassay Analyzer is a chemiluminescent immunoassay analyzer that can diagnose allergies. It's made to assist with analyte concentration measurements in human samples.
In September 2021, The FDA granted breakthrough device Designation to Oncuria, a revolutionary non-invasive multiplex immunoassay used to predict therapeutic response in patients with bladder cancer, as a. Nonagen Bioscience Corp's gadget analyses ten protein biomarkers in a single urine sample. Biomarker levels are then used to help predict Bacillus Calmette-Guerin (BCG) response in patients with intermediate-to-high-risk, early-stage bladder cancer using a weighted algorithm.
Various products that key market leaders develop
Product
Function
Key players
ABBOTT PRISM System
Automated immunoassay analyzer designed to perform Chemiluminescent immunoassay (ChLIA) technology.
Phadia 250
Immunoassay Analyzers that Provide optimal allergy and autoimmunity testing solutions.
Thermo Fisher Scientific,
VIDAS
Automated immunoassay system based on the Enzyme-Linked Fluorescent Assay (ELFA) principles.
bioMérieux
Cobas e 411
The fully automated analyser that uses ElectroChemiLuminescence (ECL) technology for immunoassay analysis.
Roche
b: The global immunoassay market size was $24.30 Bn in 2021 and is predicted to reach $45.82 Bn by 2030 with a CAGR of 7.3% during 2021-2030.
b: The global immunoassay market analysis shows a valuation of USD 24.30 Bn in 2021.
b: The global immunoassay market is expected to grow at a compound annual growth rate (CAGR) of 7.3% from 2021 to 2030 to reach USD 45.82 billion by 2030.
b: The global immunoassay market forecasts a CAGR of 7.3%.
b: Immunoassays are often used in drug discovery and pharmaceutical industries, including illness diagnostics, therapeutic medication monitoring, clinical pharmacokinetics and bioequivalence investigations.
b: Global Immunoassay market trends forecast North America with the largest share.
b: Asia-Pacific is projected to have the fastest growth rate in the Global Immunoassays Market. Factors affecting the Immunoassay market growth rate include high incidence rate rising Population, the evolution of the immunoassay market in India and the growing ELISA market size.
b: Key players in Immunoassays Market Include- BD, Bio-Techne, Abbott, Agilent Technologies, Beckman Coulter, BioCheck, bioMérieux SA, Merck KGaA, Ortho Clinical Diagnostics, Randox Laboratories Ltd, Siemens, Thermo Fisher Scientific, Shenzhen Mindray Bio-Medical Electronics Co, QIAGEN, PerkinElmer Inc, Meso Scale Diagnostics, F. Hoffmann-La Roche Ltd, DiaSorin S.p.A, Luminex Corporation, Bio-Rad Laboratories.
b: Clinical diagnostics and drug monitoring applications rapidly gain market share and vaccine development, Nephelometry and Protein microarrays.
b: Cloned enzyme donor immunoassay (CEDIA), heterogeneous immunoassays, Label-free immunoassays, Magnetic immunoassay, Memory Lymphocyte Immunostimulant Assay (MELISA), non-competitive immunoassays, Photoacoustic Immunoassay, real-time quantitative polymerase chain reaction (RT qPCR) and Surround Optical Fiber Immunoassay (SOFIA).
Source:
https://www.creative-diagnostics.com/Immunoassay.htm
https://pubmed.ncbi.nlm.nih.gov/8100916/
https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660
https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationAgeing2019-Report.pdf
https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245375/
https://www.healthdata.org/sites/default/files/files/policy_report/2019/GBD_2017_Booklet.pdf
https://jamanetwork.com/journals/jama/fullarticle/768249
https://www.icjournal.org/DOIx.php?id=10.3947/ic.2014.46.1.1
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K220162
1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Immunoassay Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Immunoassay Market 4.2.1 market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 market, by region, 2021-2030 (USD Million) 4.4 By Type/ Platform Business Analysis 4.4.1 market, By Type/ Platform, 2021-2030 (USD Million) 4.5 By Application Business Analysis 4.5.1 market, By Application, 2021-2030 (USD Million) 4.6 Technique Business Analysis 4.6.1 market, By Technique, 2021-2030 (USD Million) 4.7 End-user Business Analysis 4.7.1 market, By End-user, 2021-2030 (USD Million) 4.8 Product Analysis 4.8.1 market, By Product, 2021-2030 (USD Million) 4.9 Specimen Type Analysis 4.9.1 market, By Specimen Type, 2021-2030 (USD Million) 4.10 Value Chain Analysis 4.11 Market Variable Analysis 4.11.1 Market Drivers Analysis 4.11.2 Market Restraints Analysis 4.12 Business Environment Analysis Tool 4.12.1 market PEST analysis 4.12.2 market Porter’s analysis 4.13 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. End-user Analysis 5.11.1. Trends in End-user (2014-2020) 5.11.2. Trends in End-user (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By Region, By Country) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Type/ Platform 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Market: By Type/ Platform Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Radioimmunoassay (RIA) 7.3.1. Radioimmunoassay (RIA) market, 2021-2030 (USD Million) 7.4. Enzyme Immunoassays (EIA) 7.4.1. Enzyme Immunoassays (EIA) market, 2021-2030 (USD Million) 7.5. Fluoro immunoassay (FIA) 7.5.1. Fluoro immunoassay (FIA) market, 2021-2030 (USD Million) 7.6. Chemiluminescence immunoassay (CLIA) 7.6.1. Chemiluminescence immunoassay (CLIA) market, 2021-2030 (USD Million) 7.7. Electrochemiluminescence immunoassay (ECL) 7.7.1. Electrochemiluminescence immunoassay (ECL) market, 2021-2030 (USD Million) 7.8. Colloidal Gold Immunochromatographic Assay 7.8.1. Colloidal Gold Immunochromatographic Assay market, 2021-2030 (USD Million) 8. Market: By Application Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Infectious Diseases 8.3.1. Infectious Diseases market, 2021-2030 (USD Million) 8.4. Respiratory Disease 8.4.1. Respiratory Disease market, 2021-2030 (USD Million) 8.5. Oncology or Cancer Diagnostics 8.5.1. Oncology or Cancer Diagnostics market, 2021-2030 (USD Million) 8.6. Hematology 8.6.1. Hematology market, 2021-2030 (USD Million) 8.7. Cardiology 8.7.1. Cardiology market, 2021-2030 (USD Million) 8.8. Endocrinology 8.8.1. Endocrinology market, 2021-2030 (USD Million) 8.9. Thyroid 8.9.1. Thyroid market, 2021-2030 (USD Million) 8.10. Allergies 8.10.1. Allergies market, 2021-2030 (USD Million) 8.11. Others 8.11.1. Others market, 2021-2030 (USD Million) 9. Market: By Technique Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Western Blotting 9.3.1. Western Blotting market, 2021-2030 (USD Million) 9.4. Enzyme-Linked Immunosorbent Assays 9.4.1. Enzyme-Linked Immunosorbent Assays market, 2021-2030 (USD Million) 9.5. Immuno-PCR (I-PCR) 9.5.1. Immuno-PCR (I-PCR) market, 2021-2030 (USD Million) 9.6. Rapid Tests 9.6.1. Rapid Tests market, 2021-2030 (USD Million) 9.7. Enzyme-Linked Immunospot 9.7.1. Enzyme-Linked Immunospot market, 2021-2030 (USD Million) 9.8. CD/DVD based immunoassay 9.8.1. CD/DVD based immunoassay market, 2021-2030 (USD Million) 9.9. Other Techniques 9.9.1. Other Techniques market, 2021-2030 (USD Million) 10. Market: By End-user Segment Analysis 10.1. Introduction 10.2. Sales Volume & Revenue Analysis (2021-2030) 10.3. Hospitals 10.3.1. Hospitals market, 2021-2030 (USD Million) 10.4. Pharma & Biotech Companies 10.4.1. Pharma & Biotech Companies market, 2021-2030 (USD Million) 10.5. Clinical Laboratories 10.5.1. Clinical Laboratories market, 2021-2030 (USD Million) 10.6. Others 10.6.1. Others market, 2021-2030 (USD Million) 11. Market: By Product Segment Analysis 11.1. Introduction 11.2. Sales Volume & Revenue Analysis (2021-2030) 11.3. Reagents and Kits 11.3.1. Reagents and Kits market, 2021-2030 (USD Million) 11.4. Analyzers 11.4.1. Analyzers market, 2021-2030 (USD Million) 12. Market: By Specimen Type Segment Analysis 12.1. Introduction 12.2. Sales Volume & Revenue Analysis (2021-2030) 12.3. Blood 12.3.1. Blood market, 2021-2030 (USD Million) 12.4. Saliva 12.4.1. Saliva market, 2021-2030 (USD Million) 12.5. Urine 12.5.1. Urine market, 2021-2030 (USD Million) 12.6. Others 12.6.1. Others market, 2021-2030 (USD Million) 13. Market: Regional Outlook 13.1 North America 13.1.1. North America market, By Type/ Platform, 2021-2030 (USD Million) 13.1.2. North America market, By Application, 2021-2030 (USD Million) 13.1.3. North America market, by End-user, 2021-2030 (USD Million) 13.1.4. North America market, by Specimen Type, 2021-2030 (USD Million) 13.1.5. North America market, by Product, 2021-2030 (USD Million) 13.1.6. North America market, by Country, 2021-2030 (USD Million) 12.1.4.1. U.S. 12.1.4.1.1. U.S. market, By Type/ Platform, 2021-2030 (USD Million) 12.1.4.1.2. U.S. market, By Application, 2021-2030 (USD Million) 12.1.4.1.3. U.S. market, by End-user, 2021-2030 (USD Million) 12.1.4.1.4. U.S. market, by Specimen Type, 2021-2030 (USD Million) 12.1.4.1.5. U.S. market, by Product, 2021-2030 (USD Million) 12.1.4.1.6. U.S. market, by Country, 2021-2030 (USD Million) 12.1.4.2. Canada 12.1.4.2.1. Canada market, By Type/ Platform, 2021-2030 (USD Million) 12.1.4.2.2. Canada market, By Application, 2021-2030 (USD Million) 12.1.4.2.3. Canada market, by End-user, 2021-2030 (USD Million) 12.2. Europe 12.2.1. Europe market, By Type/ Platform, 2021-2030 (USD Million) 12.2.2. Europe market, By Application, 2021-2030 (USD Million) 12.2.3. Europe market, by End-user, 2021-2030 (USD Million) 12.2.4. Europe market, by Specimen Type, 2021-2030 (USD Million) 12.2.5. Europe market, by Product, 2021-2030 (USD Million) 12.2.6. Europe market, by country, 2021-2030 (USD Million) 12.2.4.1 U.K. 12.2.4.1.1. U.K. market, By Type/ Platform, 2021-2030 (USD Million) 12.2.4.1.2. U.K. market, By Application, 2021-2030 (USD Million) 12.2.4.1.3. U.K. market, by End-user, 2021-2030 (USD Million) 12.2.4.2. Germany 12.2.4.2.1. Germany market, By Type/ Platform, 2021-2030 (USD Million) 12.2.4.2.2. Germany market, By Application, 2021-2030 (USD Million) 12.2.4.2.3. Germany market, by End-user, 2021-2030 (USD Million) 12.2.4.3. France 12.2.4.3.1. France market, By Type/ Platform, 2021-2030 (USD Million) 12.2.4.3.2. France market, By Application, 2021-2030 (USD Million) 12.2.4.3.3. France market, by End-user, 2021-2030 (USD Million) 12.2.4.4. Rest of Europe 12.2.4.4.1. Rest of Europe market, By Type/ Platform, 2021-2030 (USD Million) 12.2.4.4.2. Rest of Europe market, By Application, 2021-2030 (USD Million) 12.2.4.4.3. Rest of Europe market, by End-user, 2021-2030 (USD Million) 12.3. Asia Pacific 12.3.1. Asia Pacific market, By Type/ Platform, 2021-2030 (USD Million) 12.3.2. Asia Pacific market, By Application, 2021-2030 (USD Million) 12.3.3. Asia Pacific market, by End-user, 2021-2030 (USD Million) 12.3.4. Asia Pacific market, by Specimen Type, 2021-2030 (USD Million) 12.3.5. Asia Pacific market, by Product, 2021-2030 (USD Million) 12.3.6. Asia Pacific market, by country, 2021-2030 (USD Million) 12.3.4.1. China 12.3.4.1.1. China market, By Type/ Platform, 2021-2030 (USD Million) 12.3.4.1.2. China market, By Application, 2021-2030 (USD Million) 12.3.4.1.3. China market, by End-user, 2021-2030 (USD Million) 12.3.4.2. India 12.3.4.2.1. India market, By Type/ Platform, 2021-2030 (USD Million) 12.3.4.2.2. India market, By Application, 2021-2030 (USD Million) 12.3.4.2.3. India market, by End-user, 2021-2030 (USD Million) 12.3.4.3. Japan 12.3.4.3.1. Japan market, By Type/ Platform, 2021-2030 (USD Million) 12.3.4.3.2. Japan market, By Application, 2021-2030 (USD Million) 12.3.4.3.3. Japan market, by End-user, 2021-2030 (USD Million) 12.3.4.4. South Korea 12.3.4.4.1. South Korea market, By Type/ Platform, 2021-2030 (USD Million) 12.3.4.4.2. South Korea market, By Application, 2021-2030 (USD Million) 12.3.4.4.3. South Korea market, by End-user, 2021-2030 (USD Million) 12.3.4.5. Rest of ASIA PACIFIC 12.3.4.5.1. Rest of ASIA PACIFIC market, By Type/ Platform, 2021-2030 (USD Million) 12.3.4.5.2. Rest of ASIA PACIFIC market, By Application, 2021-2030 (USD Million) 12.3.4.5.3. Rest of ASIA PACIFIC market, by End-user, 2021-2030 (USD Million) 12.4. Latin America 12.4.1. Latin America market, By Type/ Platform, 2021-2030 (USD Million) 12.4.2. Latin America market, By Application, 2021-2030 (USD Million) 12.4.3. Latin America market, by End-user, 2021-2030 (USD Million) 12.4.4. Latin America market, by Specimen Type, 2021-2030 (USD Million) 12.4.5. Latin America market, by product, 2021-2030 (USD Million) 12.4.6. Latin America market, by Technique, 2021-2030 (USD Million) 12.4.7. Latin America market, by country, 2021-2030 (USD Million) 12.4.4.1. Brazil 12.4.4.1.1. Brazil market, By Type/ Platform, 2021-2030 (USD Million) 12.4.4.1.2. Brazil market, By Application, 2021-2030 (USD Million) 12.4.4.1.3. Brazil market, by End-user, 2021-2030 (USD Million) 12.4.4.2. Mexico 12.4.4.2.1. Mexico market, By Type/ Platform, 2021-2030 (USD Million) 12.4.4.2.2. Mexico market, By Application, 2021-2030 (USD Million) 12.4.4.2.3. Mexico market, by End-user, 2021-2030 (USD Million) 12.4.4.3. Rest of the Latin America 12.4.4.3.1. Rest of the Latin America market, By Type/ Platform, 2021-2030 (USD Million) 12.4.4.3.2. Rest of the Latin America market, By Application, 2021-2030 (USD Million) 12.4.4.3.3. Rest of the Latin America market, by End-user, 2021-2030 (USD Million) 12.5. MEA 12.5.1. MEA market, By Type/ Platform, 2021-2030 (USD Million) 12.5.2. MEA market, By Application, 2021-2030 (USD Million) 12.5.3. MEA market, by End-user, 2021-2030 (USD Million) 12.5.4. MEA market, by Technique, 2021-2030 (USD Million) 12.5.4. MEA market, by Specimen Type, 2021-2030 (USD Million) 12.5.4. MEA market, by Region, 2021-2030 (USD Million) 13. Competitive Landscape 13.1 Abbott 13.1.1. Company overview 13.1.2. Financial performance 13.1.3. Type/ Platform Portfolio Analysis 13.1.4. Business Strategy & Recent Development 13.2. Agilent Technologies 13.2.1. Company overview 13.2.2. Financial performance 13.2.3. Type/ Platform Portfolio Analysis 13.2.4. Business Strategy & Recent Development 13.3. BD 13.3.1. Company overview 13.3.2. Financial performance 13.3.3. Type/ Platform Portfolio Analysis 13.3.4. Business Strategy & Recent Development 13.4. Beckman Coulter 13.4.1. Company overview 13.4.2. Financial performance 13.4.3. Type/ Platform Portfolio Analysis 13.4.4. Business Strategy & Recent Development 13.5. BioCheck 13.5.1. Company overview 13.5.2. Financial performance 13.5.3. Type/ Platform Portfolio Analysis 13.5.4. Business Strategy & Recent Development 13.6. bioMérieux SA 13.6.1. Company overview 13.6.2. Financial performance 13.6.3. Type/ Platform Portfolio Analysis 13.6.4. Business Strategy & Recent Development 13.7. Bio-Rad Laboratories 13.7.1. Company overview 13.7.2. Financial performance 13.7.3. Type/ Platform Portfolio Analysis 13.7.4. Business Strategy & Recent Development 13.8. Bio-Techne 13.8.1. Company overview 13.8.2. Financial performance 13.8.3. Type/ Platform Portfolio Analysis 13.8.4. Business Strategy & Recent Development 13.9. DiaSorin S.p.A 13.9.1. Company overview 13.9.2. Financial performance 13.9.3. Type/ Platform Portfolio Analysis 13.9.4. Business Strategy & Recent Development 13.10. F. Hoffmann-La Roche Ltd 13.10.1. Company overview 13.10.2. Financial performance 13.10.3. Type/ Platform Portfolio Analysis 13.10.4. Business Strategy & Recent Development 13.11. Luminex Corporation 13.11.1. Company overview 13.11.2. Financial performance 13.11.3. Type/ Platform Portfolio Analysis 13.11.4. Business Strategy & Recent Development 13.12. Merck KGaA 13.12.1. Company overview 13.12.2. Financial performance 13.12.3. Type/ Platform Portfolio Analysis 13.12.4. Business Strategy & Recent Development 13.13. Meso Scale Diagnostics 13.13.1. Company overview 13.13.2. Financial performance 13.13.3. Type/ Platform Portfolio Analysis 13.13.4. Business Strategy & Recent Development 13.14. Ortho Clinical Diagnostics 13.14.1. Company overview 13.14.2. Financial performance 13.14.3. Type/ Platform Portfolio Analysis 13.14.4. Business Strategy & Recent Development 13.15. PerkinElmer Inc 13.15.1. Company overview 13.15.2. Financial performance 13.15.3. Type/ Platform Portfolio Analysis 13.15.4. Business Strategy & Recent Development 13.16. QIAGEN 13.16.1. Company overview 13.16.2. Financial performance 13.16.3. Type/ Platform Portfolio Analysis 13.16.4. Business Strategy & Recent Development 13.17. Quidel Corporation 13.17.1. Company overview 13.17.2. Financial performance 13.17.3. Type/ Platform Portfolio Analysis 13.17.4. Business Strategy & Recent Development 13.18. Randox Laboratories Ltd 13.18.1. Company overview 13.18.2. Financial performance 13.18.3. Type/ Platform Portfolio Analysis 13.18.4. Business Strategy & Recent Development 13.18. Shenzhen Mindray Bio-Medical Electronics Co 13.18.1. Company overview 13.18.2. Financial performance 13.18.3. Type/ Platform Portfolio Analysis 13.18.4. Business Strategy & Recent Development 13.18. Siemens 13.18.1. Company overview 13.18.2. Financial performance 13.18.3. Type/ Platform Portfolio Analysis 13.18.4. Business Strategy & Recent Development 13.18. Thermo Fisher Scientific 13.18.1. Company overview 13.18.2. Financial performance 13.18.3. Type/ Platform Portfolio Analysis 13.18.4. Business Strategy & Recent Development List of Tables (86 Tables) TABLE 1. MARKET, By Type/ Platform, 2021-2030 (USD Million) TABLE 2. MARKET FOR Radioimmunoassay (RIA), BY REGION, 2021-2030 (USD Million) TABLE 3. MARKET FOR Enzyme Immunoassays (EIA), BY REGION, 2021-2030 (USD Million) TABLE 4. MARKET FOR Fluoro immnoassay (FIA), BY REGION, 2021-2030 (USD Million) TABLE 5. MARKET FOR Chemiluminescence immunoassay (CLIA), BY REGION, 2021-2030 (USD Million) TABLE 6. MARKET FOR Electrochemiluminescence immunoassay (ECL), BY REGION, 2021-2030 (USD Million) TABLE 7. MARKET FOR Colloidal Gold Immunochromatographic Assay, BY REGION, 2021-2030 (USD Million) TABLE 8. MARKET, By Application, 2021-2030 (USD Million) TABLE 9. MARKET FOR Infectious Diseases, BY REGION, 2021-2030 (USD Million) TABLE 10. MARKET FOR Respiratory Disease, BY REGION, 2021-2030 (USD Million) TABLE 11. MARKET FOR Oncology or Cancer Diagnostics, BY REGION, 2021-2030 (USD Million) TABLE 12. MARKET FOR Hematology, BY REGION, 2021-2030 (USD Million) TABLE 13. MARKET FOR Cardiology, BY REGION, 2021-2030 (USD Million) TABLE 14. MARKET FOR Endocrinology, BY REGION, 2021-2030 (USD Million) TABLE 15. MARKET FOR Thyroid, BY REGION, 2021-2030 (USD Million) TABLE 16. MARKET FOR Allergies, BY REGION, 2021-2030 (USD Million) TABLE 17. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 18. MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 19. MARKET FOR Hospitals, BY REGION, 2021-2030 (USD Million) TABLE 20. MARKET FOR Pharma & Biotech Companies, BY REGION, 2021-2030 (USD Million) TABLE 21. MARKET FOR Clinical Laboratories, BY REGION, 2021-2030 (USD Million) TABLE 22. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 23. MARKET, By Technique, 2021-2030 (USD Million) TABLE 24. MARKET FOR Western Blotting, BY REGION, 2021-2030 (USD Million) TABLE 25. MARKET FOR Enzyme-Linked Immunosorbent Assays, BY REGION, 2021-2030 (USD Million) TABLE 26. MARKET FOR Immuno-PCR (I-PCR), BY REGION, 2021-2030 (USD Million) TABLE 27. MARKET FOR Rapid Tests, BY REGION, 2021-2030 (USD Million) TABLE 28. MARKET FOR Enzyme-Linked Immunospot, BY REGION, 2021-2030 (USD Million) TABLE 29. MARKET FOR CD/DVD based immunoassay, BY REGION, 2021-2030 (USD Million) TABLE 30. MARKET FOR Other Techniques, BY REGION, 2021-2030 (USD Million) TABLE 31. MARKET, By Product, 2021-2030 (USD Million) TABLE 32. MARKET FOR Reagents and Kits, BY REGION, 2021-2030 (USD Million) TABLE 33. MARKET FOR Analyzers, BY REGION, 2021-2030 (USD Million) TABLE 34. MARKET, By Specimen Type, 2021-2030 (USD Million) TABLE 35. MARKET FOR Blood, BY REGION, 2021-2030 (USD Million) TABLE 36. MARKET FOR Saliva, BY REGION, 2021-2030 (USD Million) TABLE 37. MARKET FOR Urine, BY REGION, 2021-2030 (USD Million) TABLE 38. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 39. MARKET, BY REGION, 2021-2030 (USD Million) TABLE 40. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 41. NORTH AMERICA MARKET, By Type/ Platform, 2021-2030 (USD Million) TABLE 42. NORTH AMERICA MARKET, By Application, 2021-2030 (USD Million) TABLE 43. NORTH AMERICA MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 44. NORTH AMERICA MARKET, BY Specimen Type, 2021-2030 (USD Million) TABLE 45. NORTH AMERICA MARKET, BY Product, 2021-2030 (USD Million) TABLE 46. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 47. EUROPE MARKET, By Type/ Platform, 2021-2030 (USD Million) TABLE 48. EUROPE MARKET, By Application, 2021-2030 (USD Million) TABLE 49. EUROPE MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 50. EUROPE MARKET, BY Specimen Type, 2021-2030 (USD Million) TABLE 51. EUROPE MARKET, BY Product, 2021-2030 (USD Million) TABLE 52. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 53. ASIA-PACIFIC MARKET, By Type/ Platform, 2021-2030 (USD Million) TABLE 54. ASIA-PACIFIC MARKET, By Application, 2021-2030 (USD Million) TABLE 55. ASIA-PACIFIC MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 56. ASIA-PACIFIC MARKET, BY Specimen Type, 2021-2030 (USD Million) TABLE 57. ASIA-PACIFIC MARKET, BY Product, 2021-2030 (USD Million) TABLE 58. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 59. LAMEA MARKET, By Type/ Platform, 2021-2030 (USD Million) TABLE 60. LAMEA MARKET, By Technique, 2021-2030 (USD Million) TABLE 61. LAMEA MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 62. LAMEA MARKET, BY Specimen Type, 2021-2030 (USD Million) TABLE 63. LAMEA MARKET, BY Product, 2021-2030 (USD Million) TABLE 64. Abbott: COMPANY SNAPSHOT TABLE 65. Abbott: OPERATING SEGMENTS TABLE 66. Agilent Technologies: COMPANY SNAPSHOT TABLE 67. Agilent Technologies: OPERATING SEGMENTS TABLE 68. BD: COMPANY SNAPSHOT TABLE 69. BD: OPERATING SEGMENTS TABLE 70. Beckman Coulter: COMPANY SNAPSHOT TABLE 71. Beckman Coulter: OPERATING SEGMENTS TABLE 72. BioCheck: COMPANY SNAPSHOT TABLE 73. BioCheck: OPERATING SEGMENTS TABLE 74. bioMérieux SA: COMPANY SNAPSHOT TABLE 75. bioMérieux SA: OPERATING SEGMENTS TABLE 76. Bio-Rad Laboratories: COMPANY SNAPSHOT TABLE 77. Bio-Rad Laboratories: OPERATING SEGMENTS TABLE 78. Bio-Techne: COMPANY SNAPSHOT TABLE 79. Bio-Techne: OPERATING SEGMENTS TABLE 80. DiaSorin S.p.A: COMPANY SNAPSHOT TABLE 81. DiaSorin S.p.A: OPERATING SEGMENTS TABLE 82. F. Hoffmann-La Roche Ltd: COMPANY SNAPSHOT TABLE 83. F. Hoffmann-La Roche Ltd: OPERATING SEGMENTS TABLE 84. Luminex Corporation: COMPANY SNAPSHOT TABLE 85. Luminex Corporation: OPERATING SEGMENTS TABLE 86. Merck KGaA: COMPANY SNAPSHOT TABLE 87. Merck KGaA: OPERATING SEGMENTS TABLE 88. Meso Scale Diagnostics: COMPANY SNAPSHOT TABLE 89. Meso Scale Diagnostics: OPERATING SEGMENTS TABLE 90. Ortho Clinical Diagnostics: COMPANY SNAPSHOT TABLE 91. Ortho Clinical Diagnostics: OPERATING SEGMENTS TABLE 92. PerkinElmer Inc: COMPANY SNAPSHOT TABLE 93. PerkinElmer Inc: OPERATING SEGMENTS TABLE 94. QIAGEN: COMPANY SNAPSHOT TABLE 95. QIAGEN: OPERATING SEGMENTS TABLE 96. Quidel Corporation: COMPANY SNAPSHOT TABLE 97. Quidel Corporation: OPERATING SEGMENTS TABLE 98. Randox Laboratories Ltd: COMPANY SNAPSHOT TABLE 99. Randox Laboratories Ltd: OPERATING SEGMENTS TABLE 100. Shenzhen Mindray Bio-Medical Electronics Co: COMPANY SNAPSHOT TABLE 101. Shenzhen Mindray Bio-Medical Electronics Co: OPERATING SEGMENTS TABLE 102. Siemens: COMPANY SNAPSHOT TABLE 103. Siemens: OPERATING SEGMENTS TABLE 104. Thermo Fisher Scientific: COMPANY SNAPSHOT TABLE 105. Thermo Fisher Scientific: OPERATING SEGMENTS List of Figures (24 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Type/ Platform-Based Estimation Figure 6 Top 21 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2020 Figure 8 Import Data for Immunoassay Market, By Country, 2016–2020 (USD Thousand) Figure 9 Export Data for Immunoassay Market, By Country, 2016–2020 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market Share, By Application, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By End-user, 2019 vs. 2025 (USD Million) Figure 13 Market Share, By Type/ Platform, 2019 vs. 2025 (USD Million) Figure 14 Market Share, By Product, 2019 vs. 2025 (USD Million) Figure 15 Market Share, By Technique, 2019 vs. 2025 (USD Million) Figure 16 Market Share, By Specimen Type, 2019 vs. 2025 (USD Million) Figure 17 Geographical Snapshot of the Market Figure 18 Enzyme Immunoassays (EIA) to Witness Higher CAGR in Market for Type/ Platform Segment during Forecast Period. Figure 19 Hospitals to Witness Higher CAGR in Market for End-user Segment during Forecast Period. Figure 20 Enzyme-Linked Immunosorbent Assays to Witness Higher CAGR in Market for Technique Segment during Forecast Period. Figure 21 Reagents and Kits to Witness Higher CAGR in Market for Product Segment during Forecast Period. Figure 22 Blood to Witness Higher CAGR in Market for Specimen Type Segment during Forecast Period. Figure 23 Infectious Diseases to Witness Higher CAGR in the Market for Application Segment during Forecast Period. Figure 24 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 25 Market: Drivers, Restraints, Opportunities, and Challenges Figure 26 North America: Market Snapshot Figure 27 Asia Pacific: Market Snapshot Figure 28 Vendor Dive: Evaluation Overview
1. Introduction
1.1. Study Objective
1.2. Market Definition
1.3. Study Scope
1.3.1. Markets Covered
1.3.2. Geographic Scope
1.3.3. Years Considered
1.3.4. Stakeholders
2. Research Methodology
2.1. Data Procurement
2.2. Paid Database
2.2.1. Secondary Data
2.2.1.1. Key Secondary sources
2.2.2. Primary Data
2.2.2.1 Primary sources
2.2.2.2. Key industry insights
2.2.2.3. Primary interviews with experts
2.2.2.4. Key primary respondent list
2.3. Market Size Estimation
2.4. Bottom-Up and Top-Down Approaches
2.4.1. Bottom-Up Approach
2.4.1.1. Approach for arriving at market size by bottom-up analysis
2.4.2. Top-Down Approach
2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis
2.5. Market Breakdown and Data Triangulation
2.6. Research Methodology
2.7. Risk Assessment
3. Executive Summary
3.1 Immunoassay Market: Post-Covid-19
3.1.1 Actual Scenario
3.1.2 Pessimistic Scenario
3.1.3 Optimistic Scenario
3.1.4 Market Summary
4. Industry Outlook
4.1 Market Snapshot
4.2 Immunoassay Market
4.2.1 market, 2021 – 2030 (USD Million)
4.3 Regional Business Analysis
4.3.1 market, by region, 2021-2030 (USD Million)
4.4 By Type/ Platform Business Analysis
4.4.1 market, By Type/ Platform, 2021-2030 (USD Million)
4.5 By Application Business Analysis
4.5.1 market, By Application, 2021-2030 (USD Million)
4.6 Technique Business Analysis
4.6.1 market, By Technique, 2021-2030 (USD Million)
4.7 End-user Business Analysis
4.7.1 market, By End-user, 2021-2030 (USD Million)
4.8 Product Analysis
4.8.1 market, By Product, 2021-2030 (USD Million)
4.9 Specimen Type Analysis
4.9.1 market, By Specimen Type, 2021-2030 (USD Million)
4.10 Value Chain Analysis
4.11 Market Variable Analysis
4.11.1 Market Drivers Analysis
4.11.2 Market Restraints Analysis
4.12 Business Environment Analysis Tool
4.12.1 market PEST analysis
4.12.2 market Porter’s analysis
4.13 Penetration & Growth Prospect Mapping
5. Market Dynamics
5.1. Introduction
5.2. Market Dynamics
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Opportunities
5.2.4. Challenges
5.3. Impact of Covid-19 On Market
5.4. Value Chain Analysis
5.5. Ecosystem
5.6. Patent Analysis
5.7. Trade Analysis
5.8. Tariff Analysis
5.9. Case Study Analysis
5.10. Porter’s Five Forces Analysis
5.10.1 Threat of New Entrants
5.10.2 Threat of Substitutes
5.10.3 Bargaining Power of Buyers
5.10.4 Bargaining Power of Suppliers
5.10.5 Degree of Competition
5.11. End-user Analysis
5.11.1. Trends in End-user (2014-2020)
5.11.2. Trends in End-user (2021-2028)
5.12. Pricing Analysis
5.12.1. Average Price Trend Analysis (By Region, By Country)
6. Competitive & Vendor Landscape
6.1. Company Market Share Analysis
6.2. Manufacturers Manufacturing Sites, Area Served, Type/ Platform
6.3. Market Competitive Situation and Trends
6.4. Manufacturers Mergers & Acquisitions, Expansion Plans
7. Market: By Type/ Platform Segment Analysis
7.1. Introduction
7.2. Sales Volume & Revenue Analysis (2021-2030)
7.3. Radioimmunoassay (RIA)
7.3.1. Radioimmunoassay (RIA) market, 2021-2030 (USD Million)
7.4. Enzyme Immunoassays (EIA)
7.4.1. Enzyme Immunoassays (EIA) market, 2021-2030 (USD Million)
7.5. Fluoro immunoassay (FIA)
7.5.1. Fluoro immunoassay (FIA) market, 2021-2030 (USD Million)
7.6. Chemiluminescence immunoassay (CLIA)
7.6.1. Chemiluminescence immunoassay (CLIA) market, 2021-2030 (USD Million)
7.7. Electrochemiluminescence immunoassay (ECL)
7.7.1. Electrochemiluminescence immunoassay (ECL) market, 2021-2030 (USD Million)
7.8. Colloidal Gold Immunochromatographic Assay
7.8.1. Colloidal Gold Immunochromatographic Assay market, 2021-2030 (USD Million)
8. Market: By Application Segment Analysis
8.1. Introduction
8.2. Sales Volume & Revenue Analysis (2021-2030)
8.3. Infectious Diseases
8.3.1. Infectious Diseases market, 2021-2030 (USD Million)
8.4. Respiratory Disease
8.4.1. Respiratory Disease market, 2021-2030 (USD Million)
8.5. Oncology or Cancer Diagnostics
8.5.1. Oncology or Cancer Diagnostics market, 2021-2030 (USD Million)
8.6. Hematology
8.6.1. Hematology market, 2021-2030 (USD Million)
8.7. Cardiology
8.7.1. Cardiology market, 2021-2030 (USD Million)
8.8. Endocrinology
8.8.1. Endocrinology market, 2021-2030 (USD Million)
8.9. Thyroid
8.9.1. Thyroid market, 2021-2030 (USD Million)
8.10. Allergies
8.10.1. Allergies market, 2021-2030 (USD Million)
8.11. Others
8.11.1. Others market, 2021-2030 (USD Million)
9. Market: By Technique Segment Analysis
9.1. Introduction
9.2. Sales Volume & Revenue Analysis (2021-2030)
9.3. Western Blotting
9.3.1. Western Blotting market, 2021-2030 (USD Million)
9.4. Enzyme-Linked Immunosorbent Assays
9.4.1. Enzyme-Linked Immunosorbent Assays market, 2021-2030 (USD Million)
9.5. Immuno-PCR (I-PCR)
9.5.1. Immuno-PCR (I-PCR) market, 2021-2030 (USD Million)
9.6. Rapid Tests
9.6.1. Rapid Tests market, 2021-2030 (USD Million)
9.7. Enzyme-Linked Immunospot
9.7.1. Enzyme-Linked Immunospot market, 2021-2030 (USD Million)
9.8. CD/DVD based immunoassay
9.8.1. CD/DVD based immunoassay market, 2021-2030 (USD Million)
9.9. Other Techniques
9.9.1. Other Techniques market, 2021-2030 (USD Million)
10. Market: By End-user Segment Analysis
10.1. Introduction
10.2. Sales Volume & Revenue Analysis (2021-2030)
10.3. Hospitals
10.3.1. Hospitals market, 2021-2030 (USD Million)
10.4. Pharma & Biotech Companies
10.4.1. Pharma & Biotech Companies market, 2021-2030 (USD Million)
10.5. Clinical Laboratories
10.5.1. Clinical Laboratories market, 2021-2030 (USD Million)
10.6. Others
10.6.1. Others market, 2021-2030 (USD Million)
11. Market: By Product Segment Analysis
11.1. Introduction
11.2. Sales Volume & Revenue Analysis (2021-2030)
11.3. Reagents and Kits
11.3.1. Reagents and Kits market, 2021-2030 (USD Million)
11.4. Analyzers
11.4.1. Analyzers market, 2021-2030 (USD Million)
12. Market: By Specimen Type Segment Analysis
12.1. Introduction
12.2. Sales Volume & Revenue Analysis (2021-2030)
12.3. Blood
12.3.1. Blood market, 2021-2030 (USD Million)
12.4. Saliva
12.4.1. Saliva market, 2021-2030 (USD Million)
12.5. Urine
12.5.1. Urine market, 2021-2030 (USD Million)
12.6. Others
12.6.1. Others market, 2021-2030 (USD Million)
13. Market: Regional Outlook
13.1 North America
13.1.1. North America market, By Type/ Platform, 2021-2030 (USD Million)
13.1.2. North America market, By Application, 2021-2030 (USD Million)
13.1.3. North America market, by End-user, 2021-2030 (USD Million)
13.1.4. North America market, by Specimen Type, 2021-2030 (USD Million)
13.1.5. North America market, by Product, 2021-2030 (USD Million)
13.1.6. North America market, by Country, 2021-2030 (USD Million)
12.1.4.1. U.S.
12.1.4.1.1. U.S. market, By Type/ Platform, 2021-2030 (USD Million)
12.1.4.1.2. U.S. market, By Application, 2021-2030 (USD Million)
12.1.4.1.3. U.S. market, by End-user, 2021-2030 (USD Million)
12.1.4.1.4. U.S. market, by Specimen Type, 2021-2030 (USD Million)
12.1.4.1.5. U.S. market, by Product, 2021-2030 (USD Million)
12.1.4.1.6. U.S. market, by Country, 2021-2030 (USD Million)
12.1.4.2. Canada
12.1.4.2.1. Canada market, By Type/ Platform, 2021-2030 (USD Million)
12.1.4.2.2. Canada market, By Application, 2021-2030 (USD Million)
12.1.4.2.3. Canada market, by End-user, 2021-2030 (USD Million)
12.2. Europe
12.2.1. Europe market, By Type/ Platform, 2021-2030 (USD Million)
12.2.2. Europe market, By Application, 2021-2030 (USD Million)
12.2.3. Europe market, by End-user, 2021-2030 (USD Million)
12.2.4. Europe market, by Specimen Type, 2021-2030 (USD Million)
12.2.5. Europe market, by Product, 2021-2030 (USD Million)
12.2.6. Europe market, by country, 2021-2030 (USD Million)
12.2.4.1 U.K.
12.2.4.1.1. U.K. market, By Type/ Platform, 2021-2030 (USD Million)
12.2.4.1.2. U.K. market, By Application, 2021-2030 (USD Million)
12.2.4.1.3. U.K. market, by End-user, 2021-2030 (USD Million)
12.2.4.2. Germany
12.2.4.2.1. Germany market, By Type/ Platform, 2021-2030 (USD Million)
12.2.4.2.2. Germany market, By Application, 2021-2030 (USD Million)
12.2.4.2.3. Germany market, by End-user, 2021-2030 (USD Million)
12.2.4.3. France
12.2.4.3.1. France market, By Type/ Platform, 2021-2030 (USD Million)
12.2.4.3.2. France market, By Application, 2021-2030 (USD Million)
12.2.4.3.3. France market, by End-user, 2021-2030 (USD Million)
12.2.4.4. Rest of Europe
12.2.4.4.1. Rest of Europe market, By Type/ Platform, 2021-2030 (USD Million)
12.2.4.4.2. Rest of Europe market, By Application, 2021-2030 (USD Million)
12.2.4.4.3. Rest of Europe market, by End-user, 2021-2030 (USD Million)
12.3. Asia Pacific
12.3.1. Asia Pacific market, By Type/ Platform, 2021-2030 (USD Million)
12.3.2. Asia Pacific market, By Application, 2021-2030 (USD Million)
12.3.3. Asia Pacific market, by End-user, 2021-2030 (USD Million)
12.3.4. Asia Pacific market, by Specimen Type, 2021-2030 (USD Million)
12.3.5. Asia Pacific market, by Product, 2021-2030 (USD Million)
12.3.6. Asia Pacific market, by country, 2021-2030 (USD Million)
12.3.4.1. China
12.3.4.1.1. China market, By Type/ Platform, 2021-2030 (USD Million)
12.3.4.1.2. China market, By Application, 2021-2030 (USD Million)
12.3.4.1.3. China market, by End-user, 2021-2030 (USD Million)
12.3.4.2. India
12.3.4.2.1. India market, By Type/ Platform, 2021-2030 (USD Million)
12.3.4.2.2. India market, By Application, 2021-2030 (USD Million)
12.3.4.2.3. India market, by End-user, 2021-2030 (USD Million)
12.3.4.3. Japan
12.3.4.3.1. Japan market, By Type/ Platform, 2021-2030 (USD Million)
12.3.4.3.2. Japan market, By Application, 2021-2030 (USD Million)
12.3.4.3.3. Japan market, by End-user, 2021-2030 (USD Million)
12.3.4.4. South Korea
12.3.4.4.1. South Korea market, By Type/ Platform, 2021-2030 (USD Million)
12.3.4.4.2. South Korea market, By Application, 2021-2030 (USD Million)
12.3.4.4.3. South Korea market, by End-user, 2021-2030 (USD Million)
12.3.4.5. Rest of ASIA PACIFIC
12.3.4.5.1. Rest of ASIA PACIFIC market, By Type/ Platform, 2021-2030 (USD Million)
12.3.4.5.2. Rest of ASIA PACIFIC market, By Application, 2021-2030 (USD Million)
12.3.4.5.3. Rest of ASIA PACIFIC market, by End-user, 2021-2030 (USD Million)
12.4. Latin America
12.4.1. Latin America market, By Type/ Platform, 2021-2030 (USD Million)
12.4.2. Latin America market, By Application, 2021-2030 (USD Million)
12.4.3. Latin America market, by End-user, 2021-2030 (USD Million)
12.4.4. Latin America market, by Specimen Type, 2021-2030 (USD Million)
12.4.5. Latin America market, by product, 2021-2030 (USD Million)
12.4.6. Latin America market, by Technique, 2021-2030 (USD Million)
12.4.7. Latin America market, by country, 2021-2030 (USD Million)
12.4.4.1. Brazil
12.4.4.1.1. Brazil market, By Type/ Platform, 2021-2030 (USD Million)
12.4.4.1.2. Brazil market, By Application, 2021-2030 (USD Million)
12.4.4.1.3. Brazil market, by End-user, 2021-2030 (USD Million)
12.4.4.2. Mexico
12.4.4.2.1. Mexico market, By Type/ Platform, 2021-2030 (USD Million)
12.4.4.2.2. Mexico market, By Application, 2021-2030 (USD Million)
12.4.4.2.3. Mexico market, by End-user, 2021-2030 (USD Million)
12.4.4.3. Rest of the Latin America
12.4.4.3.1. Rest of the Latin America market, By Type/ Platform, 2021-2030 (USD Million)
12.4.4.3.2. Rest of the Latin America market, By Application, 2021-2030 (USD Million)
12.4.4.3.3. Rest of the Latin America market, by End-user, 2021-2030 (USD Million)
12.5. MEA
12.5.1. MEA market, By Type/ Platform, 2021-2030 (USD Million)
12.5.2. MEA market, By Application, 2021-2030 (USD Million)
12.5.3. MEA market, by End-user, 2021-2030 (USD Million)
12.5.4. MEA market, by Technique, 2021-2030 (USD Million)
12.5.4. MEA market, by Specimen Type, 2021-2030 (USD Million)
12.5.4. MEA market, by Region, 2021-2030 (USD Million)
13. Competitive Landscape
13.1 Abbott
13.1.1. Company overview
13.1.2. Financial performance
13.1.3. Type/ Platform Portfolio Analysis
13.1.4. Business Strategy & Recent Development
13.2. Agilent Technologies
13.2.1. Company overview
13.2.2. Financial performance
13.2.3. Type/ Platform Portfolio Analysis
13.2.4. Business Strategy & Recent Development
13.3. BD
13.3.1. Company overview
13.3.2. Financial performance
13.3.3. Type/ Platform Portfolio Analysis
13.3.4. Business Strategy & Recent Development
13.4. Beckman Coulter
13.4.1. Company overview
13.4.2. Financial performance
13.4.3. Type/ Platform Portfolio Analysis
13.4.4. Business Strategy & Recent Development
13.5. BioCheck
13.5.1. Company overview
13.5.2. Financial performance
13.5.3. Type/ Platform Portfolio Analysis
13.5.4. Business Strategy & Recent Development
13.6. bioMérieux SA
13.6.1. Company overview
13.6.2. Financial performance
13.6.3. Type/ Platform Portfolio Analysis
13.6.4. Business Strategy & Recent Development
13.7. Bio-Rad Laboratories
13.7.1. Company overview
13.7.2. Financial performance
13.7.3. Type/ Platform Portfolio Analysis
13.7.4. Business Strategy & Recent Development
13.8. Bio-Techne
13.8.1. Company overview
13.8.2. Financial performance
13.8.3. Type/ Platform Portfolio Analysis
13.8.4. Business Strategy & Recent Development
13.9. DiaSorin S.p.A
13.9.1. Company overview
13.9.2. Financial performance
13.9.3. Type/ Platform Portfolio Analysis
13.9.4. Business Strategy & Recent Development
13.10. F. Hoffmann-La Roche Ltd
13.10.1. Company overview
13.10.2. Financial performance
13.10.3. Type/ Platform Portfolio Analysis
13.10.4. Business Strategy & Recent Development
13.11. Luminex Corporation
13.11.1. Company overview
13.11.2. Financial performance
13.11.3. Type/ Platform Portfolio Analysis
13.11.4. Business Strategy & Recent Development
13.12. Merck KGaA
13.12.1. Company overview
13.12.2. Financial performance
13.12.3. Type/ Platform Portfolio Analysis
13.12.4. Business Strategy & Recent Development
13.13. Meso Scale Diagnostics
13.13.1. Company overview
13.13.2. Financial performance
13.13.3. Type/ Platform Portfolio Analysis
13.13.4. Business Strategy & Recent Development
13.14. Ortho Clinical Diagnostics
13.14.1. Company overview
13.14.2. Financial performance
13.14.3. Type/ Platform Portfolio Analysis
13.14.4. Business Strategy & Recent Development
13.15. PerkinElmer Inc
13.15.1. Company overview
13.15.2. Financial performance
13.15.3. Type/ Platform Portfolio Analysis
13.15.4. Business Strategy & Recent Development
13.16. QIAGEN
13.16.1. Company overview
13.16.2. Financial performance
13.16.3. Type/ Platform Portfolio Analysis
13.16.4. Business Strategy & Recent Development
13.17. Quidel Corporation
13.17.1. Company overview
13.17.2. Financial performance
13.17.3. Type/ Platform Portfolio Analysis
13.17.4. Business Strategy & Recent Development
13.18. Randox Laboratories Ltd
13.18.1. Company overview
13.18.2. Financial performance
13.18.3. Type/ Platform Portfolio Analysis
13.18.4. Business Strategy & Recent Development
13.18. Shenzhen Mindray Bio-Medical Electronics Co
13.18. Siemens
13.18. Thermo Fisher Scientific
List of Tables (86 Tables)
TABLE 1. MARKET, By Type/ Platform, 2021-2030 (USD Million)
TABLE 2. MARKET FOR Radioimmunoassay (RIA), BY REGION, 2021-2030 (USD Million)
TABLE 3. MARKET FOR Enzyme Immunoassays (EIA), BY REGION, 2021-2030 (USD Million)
TABLE 4. MARKET FOR Fluoro immnoassay (FIA), BY REGION, 2021-2030 (USD Million)
TABLE 5. MARKET FOR Chemiluminescence immunoassay (CLIA), BY REGION, 2021-2030 (USD Million)
TABLE 6. MARKET FOR Electrochemiluminescence immunoassay (ECL), BY REGION, 2021-2030 (USD Million)
TABLE 7. MARKET FOR Colloidal Gold Immunochromatographic Assay, BY REGION, 2021-2030 (USD Million)
TABLE 8. MARKET, By Application, 2021-2030 (USD Million)
TABLE 9. MARKET FOR Infectious Diseases, BY REGION, 2021-2030 (USD Million)
TABLE 10. MARKET FOR Respiratory Disease, BY REGION, 2021-2030 (USD Million)
TABLE 11. MARKET FOR Oncology or Cancer Diagnostics, BY REGION, 2021-2030 (USD Million)
TABLE 12. MARKET FOR Hematology, BY REGION, 2021-2030 (USD Million)
TABLE 13. MARKET FOR Cardiology, BY REGION, 2021-2030 (USD Million)
TABLE 14. MARKET FOR Endocrinology, BY REGION, 2021-2030 (USD Million)
TABLE 15. MARKET FOR Thyroid, BY REGION, 2021-2030 (USD Million)
TABLE 16. MARKET FOR Allergies, BY REGION, 2021-2030 (USD Million)
TABLE 17. MARKET FOR Others, BY REGION, 2021-2030 (USD Million)
TABLE 18. MARKET, BY END-USER, 2021-2030 (USD Million)
TABLE 19. MARKET FOR Hospitals, BY REGION, 2021-2030 (USD Million)
TABLE 20. MARKET FOR Pharma & Biotech Companies, BY REGION, 2021-2030 (USD Million)
TABLE 21. MARKET FOR Clinical Laboratories, BY REGION, 2021-2030 (USD Million)
TABLE 22. MARKET FOR Others, BY REGION, 2021-2030 (USD Million)
TABLE 23. MARKET, By Technique, 2021-2030 (USD Million)
TABLE 24. MARKET FOR Western Blotting, BY REGION, 2021-2030 (USD Million)
TABLE 25. MARKET FOR Enzyme-Linked Immunosorbent Assays, BY REGION, 2021-2030 (USD Million)
TABLE 26. MARKET FOR Immuno-PCR (I-PCR), BY REGION, 2021-2030 (USD Million)
TABLE 27. MARKET FOR Rapid Tests, BY REGION, 2021-2030 (USD Million)
TABLE 28. MARKET FOR Enzyme-Linked Immunospot, BY REGION, 2021-2030 (USD Million)
TABLE 29. MARKET FOR CD/DVD based immunoassay, BY REGION, 2021-2030 (USD Million)
TABLE 30. MARKET FOR Other Techniques, BY REGION, 2021-2030 (USD Million)
TABLE 31. MARKET, By Product, 2021-2030 (USD Million)
TABLE 32. MARKET FOR Reagents and Kits, BY REGION, 2021-2030 (USD Million)
TABLE 33. MARKET FOR Analyzers, BY REGION, 2021-2030 (USD Million)
TABLE 34. MARKET, By Specimen Type, 2021-2030 (USD Million)
TABLE 35. MARKET FOR Blood, BY REGION, 2021-2030 (USD Million)
TABLE 36. MARKET FOR Saliva, BY REGION, 2021-2030 (USD Million)
TABLE 37. MARKET FOR Urine, BY REGION, 2021-2030 (USD Million)
TABLE 38. MARKET FOR Others, BY REGION, 2021-2030 (USD Million)
TABLE 39. MARKET, BY REGION, 2021-2030 (USD Million)
TABLE 40. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million)
TABLE 41. NORTH AMERICA MARKET, By Type/ Platform, 2021-2030 (USD Million)
TABLE 42. NORTH AMERICA MARKET, By Application, 2021-2030 (USD Million)
TABLE 43. NORTH AMERICA MARKET, BY END-USER, 2021-2030 (USD Million)
TABLE 44. NORTH AMERICA MARKET, BY Specimen Type, 2021-2030 (USD Million)
TABLE 45. NORTH AMERICA MARKET, BY Product, 2021-2030 (USD Million)
TABLE 46. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million)
TABLE 47. EUROPE MARKET, By Type/ Platform, 2021-2030 (USD Million)
TABLE 48. EUROPE MARKET, By Application, 2021-2030 (USD Million)
TABLE 49. EUROPE MARKET, BY END-USER, 2021-2030 (USD Million)
TABLE 50. EUROPE MARKET, BY Specimen Type, 2021-2030 (USD Million)
TABLE 51. EUROPE MARKET, BY Product, 2021-2030 (USD Million)
TABLE 52. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million)
TABLE 53. ASIA-PACIFIC MARKET, By Type/ Platform, 2021-2030 (USD Million)
TABLE 54. ASIA-PACIFIC MARKET, By Application, 2021-2030 (USD Million)
TABLE 55. ASIA-PACIFIC MARKET, BY END-USER, 2021-2030 (USD Million)
TABLE 56. ASIA-PACIFIC MARKET, BY Specimen Type, 2021-2030 (USD Million)
TABLE 57. ASIA-PACIFIC MARKET, BY Product, 2021-2030 (USD Million)
TABLE 58. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million)
TABLE 59. LAMEA MARKET, By Type/ Platform, 2021-2030 (USD Million)
TABLE 60. LAMEA MARKET, By Technique, 2021-2030 (USD Million)
TABLE 61. LAMEA MARKET, BY END-USER, 2021-2030 (USD Million)
TABLE 62. LAMEA MARKET, BY Specimen Type, 2021-2030 (USD Million)
TABLE 63. LAMEA MARKET, BY Product, 2021-2030 (USD Million)
TABLE 64. Abbott: COMPANY SNAPSHOT
TABLE 65. Abbott: OPERATING SEGMENTS
TABLE 66. Agilent Technologies: COMPANY SNAPSHOT
TABLE 67. Agilent Technologies: OPERATING SEGMENTS
TABLE 68. BD: COMPANY SNAPSHOT
TABLE 69. BD: OPERATING SEGMENTS
TABLE 70. Beckman Coulter: COMPANY SNAPSHOT
TABLE 71. Beckman Coulter: OPERATING SEGMENTS
TABLE 72. BioCheck: COMPANY SNAPSHOT
TABLE 73. BioCheck: OPERATING SEGMENTS
TABLE 74. bioMérieux SA: COMPANY SNAPSHOT
TABLE 75. bioMérieux SA: OPERATING SEGMENTS
TABLE 76. Bio-Rad Laboratories: COMPANY SNAPSHOT
TABLE 77. Bio-Rad Laboratories: OPERATING SEGMENTS
TABLE 78. Bio-Techne: COMPANY SNAPSHOT
TABLE 79. Bio-Techne: OPERATING SEGMENTS
TABLE 80. DiaSorin S.p.A: COMPANY SNAPSHOT
TABLE 81. DiaSorin S.p.A: OPERATING SEGMENTS
TABLE 82. F. Hoffmann-La Roche Ltd: COMPANY SNAPSHOT
TABLE 83. F. Hoffmann-La Roche Ltd: OPERATING SEGMENTS
TABLE 84. Luminex Corporation: COMPANY SNAPSHOT
TABLE 85. Luminex Corporation: OPERATING SEGMENTS
TABLE 86. Merck KGaA: COMPANY SNAPSHOT
TABLE 87. Merck KGaA: OPERATING SEGMENTS
TABLE 88. Meso Scale Diagnostics: COMPANY SNAPSHOT
TABLE 89. Meso Scale Diagnostics: OPERATING SEGMENTS
TABLE 90. Ortho Clinical Diagnostics: COMPANY SNAPSHOT
TABLE 91. Ortho Clinical Diagnostics: OPERATING SEGMENTS
TABLE 92. PerkinElmer Inc: COMPANY SNAPSHOT
TABLE 93. PerkinElmer Inc: OPERATING SEGMENTS
TABLE 94. QIAGEN: COMPANY SNAPSHOT
TABLE 95. QIAGEN: OPERATING SEGMENTS
TABLE 96. Quidel Corporation: COMPANY SNAPSHOT
TABLE 97. Quidel Corporation: OPERATING SEGMENTS
TABLE 98. Randox Laboratories Ltd: COMPANY SNAPSHOT
TABLE 99. Randox Laboratories Ltd: OPERATING SEGMENTS
TABLE 100. Shenzhen Mindray Bio-Medical Electronics Co: COMPANY SNAPSHOT
TABLE 101. Shenzhen Mindray Bio-Medical Electronics Co: OPERATING SEGMENTS
TABLE 102. Siemens: COMPANY SNAPSHOT
TABLE 103. Siemens: OPERATING SEGMENTS
TABLE 104. Thermo Fisher Scientific: COMPANY SNAPSHOT
TABLE 105. Thermo Fisher Scientific: OPERATING SEGMENTS
List of Figures (24 Figures)
Figure 1 Market: Research Methodology Steps
Figure 2 Research Design
Figure 3 Breakdown of Primaries: Market
Figure 4 Research Methodology: Hypothesis Building
Figure 5 Market: Type/ Platform-Based Estimation
Figure 6 Top 21 Companies with Highest No. Of Patent in Last 9 Years
Figure 7 No. Of Patents Granted Per Year, 2019–2020
Figure 8 Import Data for Immunoassay Market, By Country, 2016–2020 (USD Thousand)
Figure 9 Export Data for Immunoassay Market, By Country, 2016–2020 (USD Thousand)
Figure 10 Data Triangulation Methodology
Figure 11 Market Share, By Application, 2019 vs. 2025 (USD Million)
Figure 12 Market Share, By End-user, 2019 vs. 2025 (USD Million)
Figure 13 Market Share, By Type/ Platform, 2019 vs. 2025 (USD Million)
Figure 14 Market Share, By Product, 2019 vs. 2025 (USD Million)
Figure 15 Market Share, By Technique, 2019 vs. 2025 (USD Million)
Figure 16 Market Share, By Specimen Type, 2019 vs. 2025 (USD Million)
Figure 17 Geographical Snapshot of the Market
Figure 18 Enzyme Immunoassays (EIA) to Witness Higher CAGR in Market for Type/ Platform Segment during Forecast Period.
Figure 19 Hospitals to Witness Higher CAGR in Market for End-user Segment during Forecast Period.
Figure 20 Enzyme-Linked Immunosorbent Assays to Witness Higher CAGR in Market for Technique Segment during Forecast Period.
Figure 21 Reagents and Kits to Witness Higher CAGR in Market for Product Segment during Forecast Period.
Figure 22 Blood to Witness Higher CAGR in Market for Specimen Type Segment during Forecast Period.
Figure 23 Infectious Diseases to Witness Higher CAGR in the Market for Application Segment during Forecast Period.
Figure 24 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019
Figure 25 Market: Drivers, Restraints, Opportunities, and Challenges
Figure 26 North America: Market Snapshot
Figure 27 Asia Pacific: Market Snapshot
Figure 28 Vendor Dive: Evaluation Overview